Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Tekmira Pharmaceuticals, OnCore Biopharma to merge

Wednesday, January 14, 2015 12:42 PM

Tekmira Pharmaceuticals, based in Vancouver, a developer of RNA interference (RNAi) therapeutics, and OnCore Biopharma, a Doylestown, Pa.-based biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, have agreed to merge to create a new global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

More... »


Moderna, Merck to develop messenger RNA-based antiviral vaccines

Wednesday, January 14, 2015 12:41 PM

Moderna Therapeutics has announced a license and collaboration agreement with Merck, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). Moderna’s work in the collaboration will be led by Valera, its venture focused on the development of mRNA vaccines and therapeutics to fight infectious disease. Moderna is privately held, Cambridge, Mass.-based company founded by Flagship VentureLabs.

More... »


NHS increases budget for cancer drugs fund to an expected $400M

Wednesday, January 14, 2015 12:40 PM

The NHS Cancer Drugs Fund (CDF) has published a review of drugs included in the fund and increased the budget for cancer drugs. The budget for the CDF will grow from $235 million in 2013-2014, to $329 million in 2014-2015, and an estimated $400 million from April 2015. This represents a total increase of 70% since August 2014.

More... »

Roche, Meiji and Fedora partner to explore bacterial resistance to antibiotics

Wednesday, January 14, 2015 12:38 PM

RocheMeiji Seika Pharma and Fedora have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development. Meiji Seika Pharma is a Japan-based maker of antibacterial drugs. Fedora Pharmaceuticals is headquartered in Edmonton, Alberta, Canada.

More... »

Regado Biosciences, Tobira Therapeutics to merge

Wednesday, January 14, 2015 12:34 PM

Regado Biosciences, a development stage biotechnology company based in Basking Ridge, N.J., and Tobira Therapeutics, a clinical-stage biopharmaceutical company in South San Francisco, have agreed to merge. Privately held Tobira will merge with a wholly-owned subsidiary of Regado in an all-stock transaction. The merger will create a company focused on the development of novel treatments for liver and inflammatory diseases.

More... »

Crohn's & Colitis Foundation of America, ResearchMatch partner

Wednesday, January 14, 2015 12:32 PM

ResearchMatch, a U.S.-wide, disease-neutral, volunteer research recruitment and engagement platform, is partnering with the Crohn's & Colitis Foundation of America (CCFA), a volunteer-driven organization dedicated to curing Crohn's disease and ulcerative colitis, and improving the quality of life of children and adults affected by those diseases.

More... »

goBalto releases latest update of goBalto Activate

Wednesday, January 14, 2015 12:32 PM

goBalto, a San Francisco, Calif.-based provider of cloud-based clinical study startup solutions, has released its latest version of goBalto Activate, its flagship study startup platform.

More... »

Vedanta Biosciences inks agreement with Janssen, Johnson & Johnson Innovation

Wednesday, January 14, 2015 12:29 PM

Vedanta Biosciences, a Boston-based microbiome company, has announced a license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for Vedanta's lead microbiome pharmaceutical candidate (VE202), which has demonstrated efficacy in published preclinical studies using models of autoimmune disease. The agreement was facilitated by the Johnson & Johnson Innovation Center in Boston.

More... »

Greenphire receives growth investment from The Riverside Company

Wednesday, January 14, 2015 12:26 PM

Greenphire, a King of Prussia, Pa.-based provider of clinical research payment technology, has brought on global private equity firm The Riverside Company as a new growth investor. The partnership and investment is designed to further enable Greenphire to expand operational infrastructure to support its rapidly expanding global client base, expand its product suite and accelerate the company’s commercialization efforts. 

More... »

Eli Lilly inks agreements with Merck, Bristol-Myers Squibb

Wednesday, January 14, 2015 12:21 PM

Eli Lilly has formed two separate collaboration agreements. The first agreement with Merck is an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials. The second, with Bristol-Myers Squibb, is a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of BMS' immunotherapy Opdivo (nivolumab) in combination with Lilly's galunisertib (LY2157299).

More... »

CenterWatch Drugs in Clinical Trials
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs